Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia

Borghi, Claudio; Prandin, Maria Grazia; Costa, Francesco; Bacchelli, Stefano; Esposti, Daniela Degli; Ambrosioni, Ettore

doi:10.1097/00005344-200004000-00006

Cited by 133 publications

(100 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, antihypertensive therapy may affect the BP-lowering effect of statins. In previous studies, 7,8 70-100% of patients received angiotensin-converting enzyme inhibitors, whereas only 32-36% of the patients in the present study had taken angiotensin-converting enzyme inhibitors, and possible interaction with angiotensin-converting enzyme inhibitors may play an important role in the BP-lowering effect of statins.…”

Section: Discussioncontrasting

confidence: 53%

“…7,8 However, the results of the present study clearly demonstrated that long-term use of pravastatin, simvastatin, fluvastatin, and nonstatin antihyperlipidaemic drug had no additional effect on BP but significantly decreased the serum TC levels in hypertensive patients with high serum TC levels and insufficiently controlled BP despite antihypertensive therapy. This discrepancy may be attributable to the longer treatment period in the present study: the patients in previous studies received statins for only 3 or 4 months, whereas our patients received statins for 12 months.…”

Section: Discussionmentioning

confidence: 44%

“…Recent studies have shown that statins can be used to reduce BP in hypertensive patients with hypercholesterolaemia. [6][7][8] The mechanism of the reduction of BP by statins in hypertensive hyperlipidaemic patients involves the activation of endothelial nitric oxide synthase, 9 the downregulation of angiotensin II type 1 receptors, 10 and a reduction in the vascular production of reactive oxygen species. 11 In addition, the long-term administration of statins has been shown to inhibit the progression of aortic stenosis 12 and to reduce aortic stiffness, as assessed by PWV, in normotensive patients with hypercholesterolaemia.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-term effects of statins on arterial pressure and stiffness of hypertensives

et al. 2004

View full text Add to dashboard Cite

Although lowering blood pressure (BP) reduces aortic stiffness, achieving the recommended BP goal can be difficult. Recent studies have shown that short-term use of statins can reduce BP significantly. To determine the long-term effects of statins on BP and aortic stiffness, a single-blind randomized prospective study was performed on 85 hyperlipidaemic hypertensive patients whose BP was insufficiently controlled by antihypertensive therapy. Every 3 months, aortic stiffness was assessed by measuring pulse wave velocity (PWV). Patients were randomly allocated to groups treated with pravastatin, simvastatin, fluvastatin, or a nonstatin antihyperlipidaemic drug. No significant differences in patient characteristics, kinds of antihypertensive drugs, BP, ankle brachial index, PWV, or serum lipid, creatinine, or C-reactive protein levels were found between the four groups at the start of the study. During the 12-month treatment period, PWV did not change in the pravastatin group or nonstatin group, but it was transiently reduced in the simvastatin group and significantly decreased in the fluvastatin group, even though the doses of the statins used in this study were lower than the usually prescribed dose. All four antihyperlipidaemic drugs significantly decreased serum cholesterol levels without affecting BP, ankle brachial index, or serum triglyceride levels. The Creactive protein serum levels decreased significantly in the three statin groups but not in the nonstatin group. These results suggest that long-term use of fluvastatin by hyperlipidaemic hypertensive patients is associated with a significant reduction in aortic stiffness without any effect on BP.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 44%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term effects of statins on arterial pressure and stiffness of hypertensives

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Previous clinical trials reported a blood pressure lowering effect of statins in hyperlipidemic hypertensive patients who were not taking any antihypertensive drugs [39] and who had already received antihypertensive therapy [40][41][42]. The mechanisms of the reduction of blood pressure by statins in these patients included the activation of endothelial nitric oxide synthase [43], the downregulation of angiotensin II type 1 receptors [44], and a reduction in the vascular production of ROS [45].…”

Section: Discussionmentioning

confidence: 99%

The significance of lipid peroxidation in cardiovascular disease

Siegel

Ermilov

Pries

et al. 2014

Colloids and Surfaces A: Physicochemical and Engineering Aspect

View full text Add to dashboard Cite

Background: The metabolic syndrome describes a cluster of cardiovascular risk factors that frequently appear together. Its diagnosis is generally based on several well-recognized indicators in clinical practice, such as abdominal obesity, elevated triglycerides, reduced highdensity lipoprotein, raised blood pressure, and elevated fasting plasma glucose. Today, decisive importance must be attached to the metabolic syndrome since it leads to increased morbidity and mortality, and thus to a decreased life expectancy, and to higher direct and indirect healthcare costs. This is also due to the fact that its symptomatology irradiates on many organs of the body, which may thereby be damaged. Methods: In the present clinical trial on 11 metabolic syndrome patients treated with Ginkgo biloba (EGb 761, 2  120 mg/d) for two months, ellipsometry, fluorescence microscopy, photometric methods, ELISAs and EIAs were applied for biosensor profiling of metabolic syndrome risk, status and treatment outcome. Results: A spectrum of more than 20 arteriosclerotic, cytokinic, inflammatory, lipidic, and oxidative stress biomarkers served for a detailed diagnosis and therapy monitoring. After medication, the ratio oxLDL/LDL was reduced by 21.0%, 8-iso-PGF 2α 39.8%, MPO 29.6%, IL-6 12.9%, hs-CRP 39.3%, Lp(a) 26.3%, MMP-9 32.9%, insulin 9.4%, HOMA-IR 14.0%, ALP 14.8%, CREA 11.3%, URAC 10.6%, in vitro modelled nanoplaque formation 14.3% and size 23.4%, whereas SOD was augmented by 17.7%, GPx 11.6%, cAMP 43.5%, and cGMP 32.9%. Special focus was concentrated on the significance of lipid peroxidation for cardio-cerebro-vascular diseases. Through multiple correlations between the biomarkers and clinical parameters, their significance for and involvement in several clinical pictures could be elucidated. Conclusion: The present clinical observational study was helpful in unravelling this network of biomarker interactions and demonstrated its usefulness for theranostics. For personalized medicine, the selection of the biomarkers is of decisive importance. On the background of a growing obesity among children and adolescents with an increase in prevalence of the metabolic syndrome, diagnosing this syndrome in young subjects may be helpful in identifying a population of risk for increased subclinical arteriosclerosis.

show abstract

“…These results indicate that cardiologists have a deep conviction in the efficacy of statins compared with the other lipid-lowering agents. In addition to their lipid-lowering effect, statins have been reported to improve blood pressure control in hypertensive patients who have concomitant hyperlipidemia; moreover, statins are well known to prevent cardiovascular diseases (19)(20)(21)(22)(23)(24). All these beneficial effects have led physicians to consider statins as a useful intervention for atherosclerotic diseases (25).…”

Section: Drug Treatment Of Hyperlipidemiamentioning

confidence: 99%